BioSpace News Archive

Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for mavacamten, an investigational, first-in-class cardiac myosin inhibitor, for the treatment of patients with obstructive hypertrophic cardiomyopathy (obstructive HCM).

Atlas Venture today announced the closing of its second Opportunity Fund, raising $300 million in an oversubscribed fundraise.

Latch Bio today announced the closing of a $5 million seed funding round led by Lux Capital with participation from General Catalyst, Haystack, Fifty Years, and Asimov co-founder and CEO, Alec Nielsen, Ph.D.

ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa trial evaluating ICT01, a first-in-class Butyrophilin (BTN) 3A-targeting monoclonal antibody, alone and in combination with pembrolizumab in patients with advanced, relapsed/refractory solid and hematological cancers,

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data for RTX-224, a broad immune costimulatory agonist for the treatment of cancer, at the upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.

ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that four abstracts have been accepted for presentation at the SITC 36th Annual Meeting in Washington D.C. from November 10 –14, 2021.

MiNK Therapeutics, today announced acceptance of three abstracts for presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held between November 10-14, 2021.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting,

Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced that it has closed its business combination with Montes Archimedes Acquisition Corp., a special purpose acquisition company, as well as a concurrent PIPE financing.